Atlas Trials

Phase 2

89,854 clinical trials · Phase

Sort:Newest firstOldest first

◉ Watch Phase 2

RecordFirmDate
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease (NCT02577523)NeuroDerm Ltd.2015-12-29
The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy (NCT02527343)Akcea Therapeutics2015-12-28
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma (NCT02626481)University Hospital, Lille2015-12-28
Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer (NCT02618356)Fudan University2015-12-25
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 (NCT02616055)Kadmon Corporation, LLC2015-12-25
The Effect of Lovastatin Gel in the Treatment of Chronic Periodontitis (NCT03178526)Islamic Azad University, Sanandaj2015-12-24
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia (NCT02547662)Mayo Clinic2015-12-24
A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects (NCT02619851)Anterogen Co., Ltd.2015-12-23
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors (NCT02426892)M.D. Anderson Cancer Center2015-12-23
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease (NCT04958642)Mandos LLC2015-12-23
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants (NCT02624986)Hoffmann-La Roche2015-12-23
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension (NCT02639286)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2015-12-23
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting (NCT02499627)Fondazione Italiana Linfomi - ETS2015-12-23
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (NCT02508636)University of California, San Francisco2015-12-22
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02596971)Hoffmann-La Roche2015-12-22
Prostvac in Patients With Biochemically Recurrent Prostate Cancer (NCT02649439)National Cancer Institute (NCI)2015-12-22
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer (NCT02635009)NRG Oncology2015-12-22
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) (NCT02633800)Daiichi Sankyo2015-12-22
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (NCT02601950)Epizyme, Inc.2015-12-22
HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma (NCT02370160)Masonic Cancer Center, University of Minnesota2015-12-21
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) (NCT02440789)Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections2015-12-21
A Study of A-101 Solution in Subjects With Common Warts. (NCT02669862)Aclaris Therapeutics, Inc.2015-12-21
IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency (NCT02636270)Children's Hospital Medical Center, Cincinnati2015-12-21
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933)City of Hope Medical Center2015-12-21
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer (NCT03147963)Zhejiang Cancer Hospital2015-12-20
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency (NCT02004691)Genzyme, a Sanofi Company2015-12-18
Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (NCT02395692)National Cancer Institute (NCI)2015-12-18
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients (NCT02611882)Thomas Hope2015-12-18
Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity (NCT02647944)Mayo Clinic2015-12-18
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (NCT02628067)Merck Sharp & Dohme LLC2015-12-18
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) (NCT02584634)Pfizer2015-12-18
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (NCT02046733)ETOP IBCSG Partners Foundation2015-12-18
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia (NCT02530515)M.D. Anderson Cancer Center2015-12-18
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease (NCT02629120)National Institute of Allergy and Infectious Diseases (NIAID)2015-12-17
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (NCT02403778)University of Colorado, Denver2015-12-17
An 8-Week Refractory Chronic Cough Study (MK-7264-021) (NCT02612623)Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2015-12-17
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02623920)University of Arizona2015-12-16
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer (NCT02531932)Amy Tiersten2015-12-16
A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease. (NCT02585596)Yuhan Corporation2015-12-16
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (NCT02536339)Genentech, Inc.2015-12-16
PF-06372865 in Subjects With Photosensitive Epilepsy (NCT02564029)Pfizer2015-12-16
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (NCT02637687)Bayer2015-12-16
Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation (NCT04687111)Mark Ledwidge2015-12-16
Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B (NCT02618915)Ultragenyx Pharmaceutical Inc2015-12-16
Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant (NCT02668315)Maisonneuve-Rosemont Hospital2015-12-16
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) (NCT02612610)Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2015-12-15
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis (NCT02655679)Vitae Pharmaceuticals, Inc.2015-12-15
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours (NCT02591030)Centre Hospitalier Universitaire de Saint Etienne2015-12-15
The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer (NCT02653755)Dana-Farber Cancer Institute2015-12-15
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (NCT02533180)National Institute of Allergy and Infectious Diseases (NIAID)2015-12-15
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (NCT02686658)IVERIC bio, Inc.2015-12-15
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (NCT02651987)Ipsen2015-12-15
Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine (NCT02466750)U.S. Army Medical Research and Development Command2015-12-15
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression (NCT02614547)Supernus Pharmaceuticals, Inc.2015-12-15
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension (NCT02603809)Idorsia Pharmaceuticals Ltd.2015-12-14
An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis (NCT02601300)Celgene2015-12-14
AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa (NCT02556736)AbbVie2015-12-14
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma (NCT02633137)Memorial Sloan Kettering Cancer Center2015-12-14
Study Examining PrEP-001 in Subjects With Asthma (NCT03296917)Hvivo2015-12-11
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (NCT02654119)University of Nebraska2015-12-11
Fr1da Insulin Intervention (NCT02620072)Technical University of Munich2015-12-11
A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection (NCT02532283)Janssen Research & Development, LLC2015-12-11
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo (NCT02598388)Janssen Vaccines & Prevention B.V.2015-12-10
The Effectiveness of Topical Silver Colloid in Treating Patients With Recalcitrant Chronic Rhinosinusitis (NCT02403479)London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's2015-12-10
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab (NCT01931098)National Cancer Institute (NCI)2015-12-10
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) (NCT02613403)Merck Sharp & Dohme LLC2015-12-10
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer (NCT01972919)Medical College of Wisconsin2015-12-10
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL (NCT02514083)National Heart, Lung, and Blood Institute (NHLBI)2015-12-09
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus (NCT02548585)MedImmune LLC2015-12-09
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis (NCT02589665)Eli Lilly and Company2015-12-09
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer (NCT02607228)Gilead Sciences2015-12-08
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients (NCT02582684)Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections2015-12-08
Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease (NCT02513498)Fred Hutchinson Cancer Center2015-12-08
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia (NCT02530476)M.D. Anderson Cancer Center2015-12-08
Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa (NCT02579369)Anterogen Co., Ltd.2015-12-08
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients (NCT02088060)Central Institute of Mental Health, Mannheim2015-12-08
In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects (NCT02521792)Clementia Pharmaceuticals Inc.2015-12-07
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer (NCT02613221)Takeda2015-12-07
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza (NCT02603952)MedImmune LLC2015-12-07
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study- (NCT02623738)Santen Pharmaceutical Co., Ltd.2015-12-06
Treatment of Peri-calcification Edema in Neurocysticercosis (NCC) (NCT02945527)Universidad Peruana Cayetano Heredia2015-12-04
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) (NCT02633956)Intercept Pharmaceuticals2015-12-04
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (NCT02621021)National Cancer Institute (NCI)2015-12-04
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (NCT02659098)Janssen Research & Development, LLC2015-12-04
A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy (NCT02569801)Genentech, Inc.2015-12-04
To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease (NCT02601560)MedImmune LLC2015-12-03
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) (NCT02610140)Bayer2015-12-03
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy (NCT02625090)UCB Biopharma SRL2015-12-03
MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial (NCT02678923)The Medicines Company2015-12-03
Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion (NCT03330249)Groupe Oncologie Radiotherapie Tete et Cou2015-12-03
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors (NCT02605083)Effector Therapeutics2015-12-03
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) (NCT02559687)Merck Sharp & Dohme LLC2015-12-02
Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff (NCT02538939)Nantes University Hospital2015-12-02
Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD (NCT02515669)Hoffmann-La Roche2015-12-02
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (NCT02431559)Ludwig Institute for Cancer Research2015-12-02
Cardiometabolic Effects of Eplerenone in HIV Infection (NCT02629094)National Institute of Allergy and Infectious Diseases (NIAID)2015-12-02
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (NCT02965092)Wuhan Sian Medical Technology Co., Ltd2015-12-02
Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer (NCT03381352)Chinese Academy of Medical Sciences2015-12-02
Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02509052)City of Hope Medical Center2015-12-02
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) (NCT02576990)Merck Sharp & Dohme LLC2015-12-02
← Previous Next →

Track Phase 2 automatically

Every clearance here is in the API, with alerts when new ones post.